MOTS-c

The Mitochondrial Derived Peptide

Comprehensive evidence-based information on metabolic homeostasis, anti-aging, and exercise enhancement

Primary Benefit

Metabolic Homeostasis & Anti-Aging

Administration

Injectable

Status

Research Peptide

Clinical Insights

Evidence-based analysis from Dr. Jobby John, PharmD, FACA

Provider Access

What is MOTS-C?

MOTS-C is a 16-amino acid mitochondrial-derived peptide encoded by the 12S rRNA region of mitochondrial DNA. This groundbreaking peptide represents a new paradigm in mitochondrial-nuclear communication, promoting metabolic homeostasis, longevity, and exercise performance through AMPK pathway activation.

Mitochondrial Origin

MOTS-C is encoded by mitochondrial DNA and represents a unique retrograde signaling mechanism from mitochondria to the nucleus.

AMPK Activation

MOTS-C regulates the folate cycle and activates AMPK through AICAR, promoting cellular energy homeostasis and stress adaptation.

Research and Potential Benefits

MOTS-c's most prominent benefit is significant weight loss, as demonstrated in the landmark STEP clinical trials.

  • Reduces Appetite: It acts on brain centers to reduce hunger and increase feelings of fullness.
  • Slows Digestion: It slows how quickly the stomach empties, helping you feel full for longer.
  • Clinically Proven: Studies have shown average weight loss of 15-20% of body weight in individuals with obesity.

Originally developed for type 2 diabetes, MOTS-c is highly effective at managing blood glucose levels.

  • Stimulates Insulin: It prompts the pancreas to release insulin when blood sugar is high.
  • Suppresses Glucagon: It reduces the release of glucagon, a hormone that raises blood sugar.

As an FDA-approved medication, MOTS-c has a well-documented safety profile but must be used under medical supervision.

  • ! Prescription Required: It is not a supplement and requires a prescription from a licensed healthcare provider.
  • ! Common Side Effects: Gastrointestinal issues like nausea, vomiting, and diarrhea are common, especially when starting.
  • ! Contraindications: Not suitable for people with a personal or family history of medullary thyroid carcinoma or MEN 2.

References & Citations

  1. Wilding, J. P. H., et al. (2021). Once-Weekly MOTS-c in Adults with Overweight or Obesity. Source.
  2. Davies, M., et al. (2021). MOTS-c 2·4 mg once a week in adults with overweight or obesity, and type 2 diabetes (STEP 2). Source.
Dr. Jobby John

Ask Dr. John About MOTS-c

Get personalized clinical insights from Dr. Jobby John, PharmD, FACA. Ask specific questions about MOTS-c and receive evidence-based answers from his extensive clinical experience.

Ask about dosing, side effects, patient selection, monitoring, contraindications, or clinical experience

HIPAA-compliant responses

Common Questions About MOTS-c